gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2020-30-1-7-13gastro-j-303Research ArticleОБЗОРЫREVIEWSВоспалительные заболевания кишечника и статиныInflammatory Bowel Disease and Statinshttps://orcid.org/0000-0001-5902-3803ГенкельВ. В.GenkelV. V.

Cand. Sci. (Med.), Ass. Prof., Department of Internal Disease Propaedeutics

454092, Chelyabinsk, Vorovskogo str., 64

henkel-07@mail.ruhttps://orcid.org/0000-0002-7731-7730ШапошникИ. И.ShaposhnikI. I.

доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней

454092, г. Челябинск, ул. Воровского, д. 64

Dr. Sci. (Med.), Prof., Departmental Head, Department of Internal Disease Propaedeutics

454092, Chelyabinsk, Vorovskogo str., 64

shaposhnik@yandex.ruФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSouth-Ural State Medical UniversityRussian Federation202023022020301713Copyright © Генкель В.В., Шапошник И.И., 20202020Генкель В.В., Шапошник И.И.Genkel V.V., Shaposhnik I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/303Цель обзора

Цель обзора. Представить современные данные о возможностях применения статинов у пациентов с воспалительными заболеваниями кишечника (ВЗК).

Основные положения

Основные положения. Статины обладают иммуномодулирующими эффектами, изучение которых в лечении ВЗК представляет интерес. Приведены результаты экспериментальных исследований, в которых были продемонстрированы положительные эффекты статинов на различные характеристики течения ВЗК. Применение статинов приводило к снижению гистологической активности на моделях с DSS- и TNBS-индуцированными колитами. Показано снижение эпителиальной проницаемости и уменьшение крипт на фоне применения правастатина. Установлено изменение состава кишечной микрофлоры под действием симвастатина, имеющее потенциальное противовоспалительное действие. Представлены результаты клинических исследований, в которых назначение аторвастатина больным с ВЗК приводило к статистически значимому снижению сывороточных маркеров воспаления и индексу активности язвенного колита. Ретроспективные клинические исследования показали различное влияние статинов на риск возникновения ВЗК.

Заключение

Заключение. В настоящее время установлен ряд потенциально протективных эффектов статинов в отношении воспалительных заболеваний кишечника. Необходимо проведение хорошо планированных рандомизированных клинических исследований, которые позволят оценить эффекты статинов при ВЗК.

Aim

Aim. To present up-to-date information on the possibility of using statins in patients with inflammatory bowel disease (IBD).

Highlights

Highlights. Statins exhibit immunomodulatory effects, which are of particular importance with regard to IBD treatment. Experimental studies, which demonstrate positive effects of statins on various characteristics of the IBD course, were reviewed. The use of statins led to a decrease in the histological activity in models with DSS- and TNBSinduced colitis. Pravastatin was shown to decrease both the epithelial permeability and crypts. Simvastatin changed the composition of the intestinal microflora, which had a potential anti-inflammatory effect. According to the results of clinical studies, atorvastatin administration to IBD patients resulted in a statistically significant decrease in the serum markers of inflammation and the activity index of ulcerative colitis. Retrospective clinical studies demonstrated different effects of statins on the risk of IBD.

Conclusions

Conclusions. A number of potentially protective effects of statins on inflammatory bowel diseases have been identified. However, well-planned randomised clinical trials are needed to evaluate the effects of statins in IBD.

статинывоспалительные заболевания кишечникавоспалениеколоректальный ракязвенный колитболезнь Кронаstatinsinflammatory bowel diseaseinflammationcolorectal cancerulcerative colitisCrohn's diseaseЮжно-Уральский государственный медицинский университетSouth-Ural State Medical UniversityReferencesNg S.C., Shi H.Y., Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78. DOI: 10.1016/S0140-6736(17)32448-0Ng S.C., Shi H.Y., Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78. DOI: 10.1016/S0140-6736(17)32448-0Bigeh A., Sanchez A., Maestas C., Gulati M. Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease? Trends Cardiovasc Med. 2019;S1050-1738(19)30139-2. DOI: 10.1016/j.tcm.2019.10.001Bigeh A., Sanchez A., Maestas C., Gulati M. Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease? Trends Cardiovasc Med. 2019;S1050-1738(19)30139-2. DOI: 10.1016/j.tcm.2019.10.001Zeiser R. Immune modulatory effects of statins. Immunology. 2018;154(1):69–75. DOI: 10.1111/imm.12902Zeiser R. Immune modulatory effects of statins. Immunology. 2018;154(1):69–75. DOI: 10.1111/imm.12902Tuñón J., Badimón L., Bochaton-Piallat M.L., et al. Identifying the anti-inflammatory response to lipid lowering therapy: A Position Paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovasc Res. 2019 Jan 1;115(1):10–9. DOI: 10.1093/cvr/cvy293Tuñón J., Badimón L., Bochaton-Piallat M.L., et al. Identifying the anti-inflammatory response to lipid lowering therapy: A Position Paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovasc Res. 2019 Jan 1;115(1):10–9. DOI: 10.1093/cvr/cvy293Antonopoulos A.S., Margaritis M., Lee R., et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–30. DOI: 10.2174/138161212799504803Antonopoulos A.S., Margaritis M., Lee R., et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–30. DOI: 10.2174/138161212799504803Hechinger A.K., Maas K., Dürr C., et al. Inhibition of protein geranylgeranylation and farnesylation protects against GvHD via effects on CD4 effector T cells. Haematologica. 2013;98:31–40. DOI: 10.3324/haematol.2012.065789Hechinger A.K., Maas K., Dürr C., et al. Inhibition of protein geranylgeranylation and farnesylation protects against GvHD via effects on CD4 effector T cells. Haematologica. 2013;98:31–40. DOI: 10.3324/haematol.2012.065789Yoshimura K., Nagasawa A., Kudo J., et al. Inhibitory effect of statins on inflammation-related pathways in human abdominal aortic aneurysm tissue. Int J Mol Sci. 2015;16(5):11213–28. DOI: 10.3390/ijms160511213Yoshimura K., Nagasawa A., Kudo J., et al. Inhibitory effect of statins on inflammation-related pathways in human abdominal aortic aneurysm tissue. Int J Mol Sci. 2015;16(5):11213–28. DOI: 10.3390/ijms160511213Bekkering S., Arts R.J.W., Novakovic B., et al. Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell 2018;172:135–46. DOI: 10.1016/j.cell.2017.11.025Bekkering S., Arts R.J.W., Novakovic B., et al. Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell 2018;172:135–46. DOI: 10.1016/j.cell.2017.11.025Domínguez-Andrés J., Joosten L.A., Netea M.G. Induction of innate immune memory: the role of cellular metabolism. Curr Opin Immunol. 2018;56:10–16. DOI: 10.1016/j.coi.2018.09.001Domínguez-Andrés J., Joosten L.A., Netea M.G. Induction of innate immune memory: the role of cellular metabolism. Curr Opin Immunol. 2018;56:10–16. DOI: 10.1016/j.coi.2018.09.001van der Heijden C.D.C.C., Noz M.P., Joosten L.A.B., et al. Epigenetics and Trained Immunity. Antioxid Redox Signal. 2018;29(11):1023–40. DOI: 10.1089/ars.2017.7310van der Heijden C.D.C.C., Noz M.P., Joosten L.A.B., et al. Epigenetics and Trained Immunity. Antioxid Redox Signal. 2018;29(11):1023–40. DOI: 10.1089/ars.2017.7310Côté-Daigneault J., Mehandru S., Ungaro R., et al. Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(3):724–32. DOI: 10.1097/MIB.0000000000000640Côté-Daigneault J., Mehandru S., Ungaro R., et al. Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(3):724–32. DOI: 10.1097/MIB.0000000000000640Naito Y., Katada K., Takagi T., et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med. 2006;17:997–1004. DOI: 10.3892/ijmm.17.6.997Naito Y., Katada K., Takagi T., et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med. 2006;17:997–1004. DOI: 10.3892/ijmm.17.6.997Lee J.Y., Kim J.S., Kim J.M., et al. Simvastatin inhibits NF-KappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol. 2007;7:241–8. DOI: 10.1016/j.intimp.2006.10.013Lee J.Y., Kim J.S., Kim J.M., et al. Simvastatin inhibits NF-KappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol. 2007;7:241–8. DOI: 10.1016/j.intimp.2006.10.013Ikeda M., Takeshima F., Isomoto H., et al. Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not Oxazalone-induced colitis. Dig Dis Sci. 2008;53:1869–75. DOI: 10.1007/s10620-007-0102-0Ikeda M., Takeshima F., Isomoto H., et al. Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not Oxazalone-induced colitis. Dig Dis Sci. 2008;53:1869–75. DOI: 10.1007/s10620-007-0102-0Aktunc E., Kayhan B., Arasli M., et al. The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis. Immunopharmacol Immunotoxicol. 2011;33:667–75. DOI: 10.3109/08923973.2011.559475Aktunc E., Kayhan B., Arasli M., et al. The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis. Immunopharmacol Immunotoxicol. 2011;33:667–75. DOI: 10.3109/08923973.2011.559475Abe Y., Murano M., Murano N., et al. Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. Dig Dis Sci. 2012;57:335–44. DOI: 10.1007/s10620-011-1879-4Abe Y., Murano M., Murano N., et al. Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. Dig Dis Sci. 2012;57:335–44. DOI: 10.1007/s10620-011-1879-4Malekinejad H., Shafie-Irannejad V., Hobbenaghi R., et al. Comparative protective effect of hawthorn berry hydroalcoholic extract, atorvastatin, and mesalamine on experimentally induced colitis in rats. J Med Food. 2013;16:593–601. DOI: 10.1089/jmf.2012.2672Malekinejad H., Shafie-Irannejad V., Hobbenaghi R., et al. Comparative protective effect of hawthorn berry hydroalcoholic extract, atorvastatin, and mesalamine on experimentally induced colitis in rats. J Med Food. 2013;16:593–601. DOI: 10.1089/jmf.2012.2672Bereswill S., Muñoz M., Fischer A., et al. Anti-inflammatory effects of Resveratrol, Curcumin and simvastatin in acute small intestinal inflammation. PLoS One. 2010;5(12):e15099. DOI: 10.1371/journal.pone.0015099Bereswill S., Muñoz M., Fischer A., et al. Anti-inflammatory effects of Resveratrol, Curcumin and simvastatin in acute small intestinal inflammation. PLoS One. 2010;5(12):e15099. DOI: 10.1371/journal.pone.0015099Jahovic N., Gedik N., Ercan F., et al. Effects of statins on experimental colitis in normocholesterolemic rats. Scand J Gastroenterol. 2006;41:954–62. DOI: 10.1080/00365520600554444Jahovic N., Gedik N., Ercan F., et al. Effects of statins on experimental colitis in normocholesterolemic rats. Scand J Gastroenterol. 2006;41:954–62. DOI: 10.1080/00365520600554444Sasaki M., Bharwani S., Jordan P., et al. The 3-hydroxy-3-methylglutarylCoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther. 2003; 305:78–85. DOI: 10.1124/jpet.102.044099Sasaki M., Bharwani S., Jordan P., et al. The 3-hydroxy-3-methylglutarylCoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther. 2003; 305:78–85. DOI: 10.1124/jpet.102.044099Mirza H., Wu Z., Teo J.D.W., et al. Statin pleiotropy prevents rho kinase-mediated intestinal epithelial barrier compromise induced by Blastocystis сysteine proteases. Cell Microbiol. 2012;14:1474–84. DOI: 10.1111/j.1462-Mirza H., Wu Z., Teo J.D.W., et al. Statin pleiotropy prevents rho kinase-mediated intestinal epithelial barrier compromise induced by Blastocystis сysteine proteases. Cell Microbiol. 2012;14:1474–84. DOI: 10.1111/j.1462-5822.2012.01814.x2012.01814.xToumi R., Soufli I., Rafa H., et al. Probiotic bacteria Lactobacillus and Bifidobacterium attenuate inflammation in dextran sulfate sodium-induced experimental colitis in mice. Int J Immunopathol Pharmacol. 2014;27(4):615–27. DOI: 10.1177/039463201402700418Toumi R., Soufli I., Rafa H., et al. Probiotic bacteria Lactobacillus and Bifidobacterium attenuate inflammation in dextran sulfate sodium-induced experimental colitis in mice. Int J Immunopathol Pharmacol. 2014;27(4):615–27. DOI: 10.1177/039463201402700418Reinoso Webb C., Koboziev I., Furr K.L., et al. Protective and pro-inflammatory roles of intestinal bacteria. Pathophysiology. 2016;23(2):67–80. DOI: 10.1016/j.pathophys.2016.02.002Reinoso Webb C., Koboziev I., Furr K.L., et al. Protective and pro-inflammatory roles of intestinal bacteria. Pathophysiology. 2016;23(2):67–80. DOI: 10.1016/j.pathophys.2016.02.002Oishi M., Tokuhara K., Miki H., et al. Temporal and spatial dependence of inflammatory biomarkers and suppression by fluvastatin in dextran sodium sulfate-induced rat colitis model. Dig Dis Sci. 2014;59:2126–35. DOI: 10.1007/s10620-014-3163-xOishi M., Tokuhara K., Miki H., et al. Temporal and spatial dependence of inflammatory biomarkers and suppression by fluvastatin in dextran sodium sulfate-induced rat colitis model. Dig Dis Sci. 2014;59:2126–35. DOI: 10.1007/s10620-014-3163-xGrip O., Janciauskiene S., Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn’s disease. Br J Pharmacol. 2008;155(7):1085–92. DOI: 10.1038/bjp.2008.369Grip O., Janciauskiene S., Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn’s disease. Br J Pharmacol. 2008;155(7):1085–92. DOI: 10.1038/bjp.2008.369Grip O., Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn’s disease. PLoS One. 2009;4(5):e5263. DOI: 10.1371/journal.pone.0005263Grip O., Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn’s disease. PLoS One. 2009;4(5):e5263. DOI: 10.1371/journal.pone.0005263Higgins P.D., Khan T., Mapili J., et al. Atorvastatin decreases Seo Index in patients with short duration of disease in ulcerative colitis: a randomized placebo-controlled clinical trial. Gastroenterology. 2006;130:A120.Higgins P.D., Khan T., Mapili J., et al. Atorvastatin decreases Seo Index in patients with short duration of disease in ulcerative colitis: a randomized placebo-controlled clinical trial. Gastroenterology. 2006;130:A120.Ungaro R., Chang H.L., Côté-Daigneault J., et al. Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease. Am J Gastroenterol. 2016;111(10):1416–23. DOI: 10.1038/ajg.2016.233Ungaro R., Chang H.L., Côté-Daigneault J., et al. Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease. Am J Gastroenterol. 2016;111(10):1416–23. DOI: 10.1038/ajg.2016.233Khalil D., Boktor M., Mortensen E.M., et al. Comparison of frequency of inflammatory bowel disease and noninfectious gastroenteritis among statin users versus nonusers. Am J Cardiol. 2015;115(10):1396–401. DOI: 10.1016/j.amjcard.2015.02.035Khalil D., Boktor M., Mortensen E.M., et al. Comparison of frequency of inflammatory bowel disease and noninfectious gastroenteritis among statin users versus nonusers. Am J Cardiol. 2015;115(10):1396–401. DOI: 10.1016/j.amjcard.2015.02.035Crockett S.D., Hansen R.A., Stürmer T., et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012;18(6):1048–56. DOI: 10.1002/ibd.21822Crockett S.D., Hansen R.A., Stürmer T., et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012;18(6):1048–56. DOI: 10.1002/ibd.21822Ananthakrishnan A.N., Cagan A., Cai T., et al. Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2016;14(7):973–9. DOI: 10.1016/j.cgh.2016.02.017Ananthakrishnan A.N., Cagan A., Cai T., et al. Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2016;14(7):973–9. DOI: 10.1016/j.cgh.2016.02.017Poynter J.N., Gruber S.B., Higgins P.D.R., et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–92. DOI: 10.1056/NEJMoa043792Poynter J.N., Gruber S.B., Higgins P.D.R., et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–92. DOI: 10.1056/NEJMoa043792Samadder N.J., Mukherjee B., Huang S.C., et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer. 2011;117:1640–8. DOI: 10.1002/cncr.25731Samadder N.J., Mukherjee B., Huang S.C., et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer. 2011;117:1640–8. DOI: 10.1002/cncr.25731Shah S.C., Glass J., Giustino G., et al. Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in patients with Inflammatory Bowel Disease. Gut Liver. 2019 Jan 15;13(1):54–61. DOI: 10.5009/gnl18178Shah S.C., Glass J., Giustino G., et al. Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in patients with Inflammatory Bowel Disease. Gut Liver. 2019 Jan 15;13(1):54–61. DOI: 10.5009/gnl18178Rea W.E., Durrant D.C., Boldy D.A. Ulcerative colitis after statin treatment. Postgrad Med J. 2002;78:286–7. DOI: 10.1136/pmj.78.919.286Rea W.E., Durrant D.C., Boldy D.A. Ulcerative colitis after statin treatment. Postgrad Med J. 2002;78:286–7. DOI: 10.1136/pmj.78.919.286Dai C., Jiang M., Sun M.J. Statins and the Risk of Inflammatory Bowel Disease. Am J Gastroenterol. 2016;111(12):1851. DOI: 10.1038/ajg.2016.412Dai C., Jiang M., Sun M.J. Statins and the Risk of Inflammatory Bowel Disease. Am J Gastroenterol. 2016;111(12):1851. DOI: 10.1038/ajg.2016.412Golomb B.A., Evans M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373–418. DOI: 10.2165/0129784-200808060-00004Golomb B.A., Evans M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373–418. DOI: 10.2165/0129784-200808060-00004Hammer G.P., du Prel J.B., Blettner M. Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. Dtsch Arztebl Int. 2009;106(41):664–8. DOI: 10.3238/arztebl.2009.0664Hammer G.P., du Prel J.B., Blettner M. Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. Dtsch Arztebl Int. 2009;106(41):664–8. DOI: 10.3238/arztebl.2009.0664Mansi I., Mortensen E. The controversy of a wider statin utilization: why? Expert Opin Drug Saf. 2013;12:327–37. DOI: 10.1517/14740338.2013.779667Mansi I., Mortensen E. The controversy of a wider statin utilization: why? Expert Opin Drug Saf. 2013;12:327–37. DOI: 10.1517/14740338.2013.779667Karlson B.W., Palmer M.K., Nicholls S.J., et al. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. Eur J Prev Cardiol. 2016;23(7):744–7. DOI: 10.1177/2047487315598710Karlson B.W., Palmer M.K., Nicholls S.J., et al. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. Eur J Prev Cardiol. 2016;23(7):744–7. DOI: 10.1177/2047487315598710Sathyapalan T., Atkin S.L., Kilpatrick E.S. Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Diabetes Care. 2010;33(9):1948–50. DOI: 10.2337/dc10-0201Sathyapalan T., Atkin S.L., Kilpatrick E.S. Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Diabetes Care. 2010;33(9):1948–50. DOI: 10.2337/dc10-0201van der Meij E., Koning G.G., Vriens P.W., et al. A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One. 2013;8(1):e53882. DOI: 10.1371/journal.pone.0053882van der Meij E., Koning G.G., Vriens P.W., et al. A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One. 2013;8(1):e53882. DOI: 10.1371/journal.pone.0053882Fujita M., Morimoto T., Ikemoto M., et al. Dose-dependency in pleiotropic effects of atorvastatin. Int J Angiol. 2007;16(3):89–91.Fujita M., Morimoto T., Ikemoto M., et al. Dose-dependency in pleiotropic effects of atorvastatin. Int J Angiol. 2007;16(3):89–91.Dobrzycka M., Spychalski P., Łachiński A.J., et al. Statins and Colorectal Cancer — A Systematic Review. Exp Clin Endocrinol Diabetes. 2018 Aug 27. DOI: 10.1055/a-0668-5692Dobrzycka M., Spychalski P., Łachiński A.J., et al. Statins and Colorectal Cancer — A Systematic Review. Exp Clin Endocrinol Diabetes. 2018 Aug 27. DOI: 10.1055/a-0668-5692Mamtani R., Lewis J.D., Scott F.I., et al. Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. PLoS Med. 2016;13(4):e1002007. DOI: 10.1371/journal.pmed.1002007Mamtani R., Lewis J.D., Scott F.I., et al. Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. PLoS Med. 2016;13(4):e1002007. DOI: 10.1371/journal.pmed.1002007Sopková J., Vidomanová E., Strnádel J., et al. The role of statins as therapeutic agents in cancer. Gen Physiol Biophys. 2017;36(5):501–11. DOI: 10.4149/gpb_2017045Sopková J., Vidomanová E., Strnádel J., et al. The role of statins as therapeutic agents in cancer. Gen Physiol Biophys. 2017;36(5):501–11. DOI: 10.4149/gpb_2017045Ehrlich A.C., Patel S., Meillier A., et al. Chemoprevention of colorectal cancer in inflammatory bowel disease. Expert Rev Anticancer Ther. 2017;17(3):247–55. DOI: 10.1080/14737140.2017.1283987Ehrlich A.C., Patel S., Meillier A., et al. Chemoprevention of colorectal cancer in inflammatory bowel disease. Expert Rev Anticancer Ther. 2017;17(3):247–55. DOI: 10.1080/14737140.2017.1283987Ehrlich A.C., Patel S., Meillier A., et al. Chemoprevention of colorectal cancer in inflammatory bowel disease. Expert Rev Anticancer Ther. 2017;17(3):247–55. DOI: 10.1080/14737140.2017.1283987

The authors declare that there are no conflicts of interest present.